肿瘤细胞治疗研究
英文原题：Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
骨肉瘤（OS）是一种常见的原发性骨肿瘤，主要影响儿童、青少年和年轻成人。
骨肉瘤（OS）是一种常见的原发性骨肿瘤，主要影响儿童、青少年和年轻成人。1970年以前，手术切除是OS的主要治疗方法，但临床结果并不理想。随后，化疗的出现改善了OS患者的预后。然而，转移或复发发生率仍然很高，且化疗有多种副作用，因此5年生存率显著较低。近年来，CAR-T（CAR-T）细胞疗法代表了一种替代性免疫治疗方法，在血液系统恶性肿瘤中具有显著潜力。然而，CAR-T细胞在OS治疗中的应用面临诸多挑战。本综述聚焦于为提高CAR-T细胞临床疗效而取得的开发进展，并讨论了克服CAR-T细胞治疗OS所面临困难的方法。
Osteosarcoma (OS) is a frequently occurring primary bone tumor, mostly affecting children, adolescents and young adults. Before 1970, surgical resection was the main treatment method for OS, but the clinical results were not promising. Subsequently, the advent of chemotherapy has improved the prognosis of patients with OS. However, there is still a high incidence of metastasis or recurrence, and chemotherapy has several side effects, thus making the 5 year survival rate markedly low. Recently, chimeric antigen receptor T (CAR T) cell therapy represents an alternative immunotherapy approach with significant potential for hematologic malignancies. Nevertheless, the application of CAR T cells in the treatment of OS faces numerous challenges. The present review focused on the advances in the development of CAR T cells to improve their clinical efficacy, and discussed ways to overcome the difficulties faced by CAR T cell therapy for OS.
MEMBER ACCOUNT
登录成功会直接打开下一页。
